We are live on ! Find out more
GC

Grimes & Company Portfolio holdings

AUM $4.62B
1-Year Est. Return 29.71%
This Fund
S&P 500
This Quarter Est. Return
-0.75%
1 Year Est. Return
+29.71%
3 Year Est. Return
+66.17%
5 Year Est. Return
+73.59%
10 Year Est. Return
+287.63%
AUM
$2.3B
AUM Growth
-$6.59M
Cap. Flow
+$16.8M
Cap. Flow %
0.73%
Top 10 Hldgs %
40.75%
Holding
312
New
11
Increased
145
Reduced
91
Closed
11

Sector Composition

Rank Sector Weight
1 Technology 11.09%
2 Healthcare 7.74%
3 Financials 4.66%
4 Industrials 4.48%
5 Communication Services 3.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ITOT icon
276
iShares Core S&P Total US Stock Market ETF
ITOT
$94.3B
$218K 0.01%
2,217
+107
+5% +$10.8K
AMD icon
277
Advanced Micro Devices
AMD
$776B
$217K 0.01%
2,104
-2,040
-49% -$209K
ALB icon
278
Albemarle
ALB
$13.9B
$214K 0.01%
+976
New +$208K
FE icon
279
FirstEnergy
FE
$28B
$214K 0.01%
6,000
GIS icon
280
General Mills
GIS
$19.1B
$214K 0.01%
3,573
IWB icon
281
iShares Russell 1000 ETF
IWB
$48.2B
$212K 0.01%
879
ON icon
282
ON Semiconductor
ON
$31.8B
$212K 0.01%
+4,637
New +$198K
DD icon
283
DuPont de Nemours
DD
$18.5B
$209K 0.01%
2,445
-138
-5% -$12.8K
GLW icon
284
Corning
GLW
$119B
$203K 0.01%
5,559
+151
+3% +$6.03K
SAM icon
285
Boston Beer
SAM
$1.91B
$203K 0.01%
399
FXB icon
286
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.8M
$201K 0.01%
1,550
JCI icon
287
Johnson Controls International
JCI
$88.8B
$201K 0.01%
2,953
-54
-2% -$3.9K
INVA icon
288
Innoviva
INVA
$1.55B
$200K 0.01%
11,991
+1,250
+12% +$18.7K
GBDC icon
289
Golub Capital BDC
GBDC
$3.34B
$166K 0.01%
+10,489
New +$165K
OCSL icon
290
Oaktree Specialty Lending
OCSL
$1.02B
$165K 0.01%
7,785
+963
+14% +$20.3K
NAK
291
Northern Dynasty Minerals
NAK
$784M
$147K 0.01%
318,950
HRTX icon
292
Heron Therapeutics
HRTX
$93.9M
$141K 0.01%
13,152
+1,262
+11% +$15.4K
AVEO
293
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$134K 0.01%
+21,640
New +$129K
HDSN
294
Hudson Technologies
HDSN
$254M
$118K 0.01%
33,422
AGRX
295
DELISTED
Agile Therapeutics
AGRX
$96K ﹤0.01%
50
+5
+11% +$11.3K
ITRM
296
DELISTED
Iterum Therapeutics
ITRM
$89K ﹤0.01%
10,594
+842
+9% +$10.4K
ASX icon
297
ASE Group
ASX
$77.3B
$85K ﹤0.01%
10,781
-1,157
-10% -$10.1K
ADMA icon
298
ADMA Biologics
ADMA
$1.96B
$61K ﹤0.01%
54,186
RBBN icon
299
Ribbon Communications
RBBN
$377M
$60K ﹤0.01%
10,030
RGLS
300
DELISTED
Regulus Therapeutics
RGLS
$49K ﹤0.01%
7,167
+841
+13% +$6.16K

Similar funds

Grimes & Company's Q3 2021 Portfolio in Review

As of Q3 2021, Grimes & Company held 312 positions worth $2.3B, down 0.29% from $2.3B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Grimes & Company's Q3 2021 filing shows 11 new, 145 increased, 91 reduced and 11 closed positions. Its largest new stake was State Street Financial Select Sector SPDR ETF: 586,638 shares worth $22M. The largest sale was iShares Core MSCI Emerging Markets ETF, an estimated $21.3M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 10% a quarter earlier, followed by Healthcare and Financials.

  • Grimes & Company's largest Q3 2021 buy was State Street Financial Select Sector SPDR ETF: 586,638 shares worth $22M.
  • Grimes & Company added most to State Street Blackstone Senior Loan ETF in Q3 2021, an estimated $13.4M increase.
  • Grimes & Company's biggest Q3 2021 reduction was iShares Core MSCI Emerging Markets ETF, cutting an estimated $21.3M.
  • Grimes & Company fully exited State Street Consumer Staples Select Sector SPDR ETF in Q3 2021, selling an estimated $16.6M.
  • Grimes & Company's ten largest holdings make up 41% of its $2.3B portfolio in Q3 2021.
  • Grimes & Company opened 11 new positions and closed 11 in Q3 2021.
  • Grimes & Company's portfolio value fell 0.29% quarter-over-quarter to $2.3B.

Based on Grimes & Company's 13F filing for Q3 2021, filed 8 Nov 2021.